SML2126
NS1209
≥98% (HPLC)
동의어(들):
(RS)-NS 1209, 2-[[[5-[4-[(Dimethylamino)sulfonyl]phenyl]-1,2,6,7,8,9-hexahydro-8-methyl-2-oxo-3H-pyrrolo[3,2-h]isoquinolin-3-ylidene]amino]oxy]-4-hydroxybutanoic acid, NS 1209, SPD 502, SPD502
로그인조직 및 계약 가격 보기
크기 선택
5 MG
₩187,775
25 MG
₩756,277
모든 사진(1)
크기 선택
보기 변경
5 MG
₩187,775
25 MG
₩756,277
About This Item
실험식(Hill 표기법):
C24H28N4O7S
CAS Number:
Molecular Weight:
516.57
MDL number:
UNSPSC 코드:
12352200
추천 제품
분석
≥98% (HPLC)
양식
powder
색상
white to beige
solubility
DMSO: 2 mg/mL, clear
저장 온도
2-8°C
SMILES string
CN1CCC(C(C2=CC=C(S(=O)(N(C)C)=O)C=C2)=CC(C3=NOC(CCO)C(O)=O)=C4NC3=O)=C4C1
InChI
1S/C24H28N4O7S/c1-27(2)36(33,34)15-6-4-14(5-7-15)17-12-18-21(19-13-28(3)10-8-16(17)19)25-23(30)22(18)26-35-20(9-11-29)24(31)32/h4-7,12,20,29H,8-11,13H2,1-3H3,(H,31,32)(H,25,26,30)
InChI key
CFJRSKULEDUDKL-UHFFFAOYSA-N
생화학적/생리학적 작용
NS1209 (SPD 502) is a potent, selective, water-soluble and in vivo long-lasting AMPA antagonist. NS1209 exhibits neuroprotective activity in animal models of stroke, neuropathic pain and epilepsy.
water-soluble and in vivo long-lasting AMPA antagonist with neuroprotective activity
Storage Class Code
11 - Combustible Solids
WGK
WGK 3
Flash Point (°F)
Not applicable
Flash Point (°C)
Not applicable
가장 최신 버전 중 하나를 선택하세요:
Jan M Keppel Hesselink
Drug development research, 78(2), 75-80 (2017-02-15)
Preclinical Research The selective AMPA (α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid) receptor antagonist, NS1209 (also known as SPD 502) has been explored in several research and development campaigns since its selection as a lead drug candidate in the early 1990s by the Danish biotechnology
Anne Sabers et al.
Epilepsy research, 106(1-2), 292-295 (2013-04-30)
Refractory status epilepticus (RSE) is a life-threatening condition that requires immediate and aggressive treatment. Unfortunately, sometimes standard antiepileptic treatment is insufficient. Furthermore, alternative therapeutic options are limited by low evidence of efficacy. The primary objective of this study was to
E O Nielsen et al.
The Journal of pharmacology and experimental therapeutics, 289(3), 1492-1501 (1999-05-21)
Accumulating preclinical data suggest that compounds that block the excitatory effect of glutamate on excitatory amino acid receptors may have neuroprotective effects and utility for the treatment of neurodegeneration after brain ischemia. In the present study, the in vitro and
활성 필터
자사의 과학자팀은 생명 과학, 재료 과학, 화학 합성, 크로마토그래피, 분석 및 기타 많은 영역을 포함한 모든 과학 분야에 경험이 있습니다..
고객지원팀으로 연락바랍니다.
